Drug intelligence / Profile preview

BC005

Development stage: Unknown
Lead developer: Dragonboat Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

BC005 is a humanized monoclonal antibody (mAb) targeting the interleukin-4 receptor (IL-4R), developed by Dragon Boat Pharmaceutical, a subsidiary of Guilin Sanjin Pharmaceutical. By binding to IL-4R, BC005 inhibits the signaling pathways of both IL-4 and IL-13, which are key drivers of Type 2 (Th2) inflammation. The drug is primarily indicated for the treatment of asthma and moderate-to-severe atopic dermatitis. BC005 features an optimized Fc sequence for an extended half-life and a high-concentration formulation (150 mg/mL) to support convenient dosing. It has successfully completed Phase I clinical trials and is currently undergoing Phase II development.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on BC005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC005.

Explore the full profile